CompletedNot Applicable

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

United States199 participantsStarted 2020-01-28

Plain-language summary

1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

Who can participate

Age range18 Years – 95 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \* Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo Clinic Rochester. Exclusion Criteria: \* Patients with preexisting CDI.

What they're measuring

Predict central diabetes insipidus development

Timeframe: 2 years

Predict lack of central diabetes insipidus development

Timeframe: 2 years

Assess relative change

Timeframe: 2 years

Trial details

NCT IDNCT04369703

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-29

View on ClinicalTrials.gov More Sellar and Suprasellar Masses trials